“Cures Within Reach is certainly one of the most important ways to help people with an unsolved disease.”

a Meniere’s disease patient
Cures Within Reach finds and funds clinical trials testing already approved therapies to fast-track safe and effective treatments for new indications. Our patient-first, disease-agnostic approach focuses on early data to catalyze follow-on funding by others.

34 ongoing projects at 29 institutions in 27 diseases in 7 countries including 8 new trials started in 2021, plus 11 more selected to start soon

Growth of New Initiatives in 2021

- Strong growth in Diversity, Equity & Inclusion (DEI), including racial/ethnic Health Disparities, trials led by US-based racial/ethnic minority underrepresented researchers and underserved researchers based in low and lower-middle income countries (LMICs): 8 new clinical trials selected to start in 2022
- Successful first year of our Veterans/Military initiative: 2 new clinical trials now ongoing
- Successful first year of our Pediatrics focus, including our 3rd annual CureAccelerator Live! for Rare Diseases event: 3 new pediatric trials now ongoing
- Two virtual patient education events held on Real World Data and Diversity of Clinical Trial Researchers and Patients
- Our first funded trial in Asia / Vietnam began

Our Newest Success Story: Brain Cancer

In 2015, CWR joined lead funder Anticancer Fund to support a proof-of-concept (POC) trial led by Dr. Marc-Eric Halatsch at Ulm University in Germany, combining 9 generic drugs with a standard chemo drug to improve glioblastoma treatment. The combination therapy was safe, and these promising results have been published in a peer-reviewed journal and presented at a key scientific conference.

CWR’s $10,000 contribution helped support this POC trial, with promising early results and planning for a larger trial underway.

Together We’re Making Real Patient Impact

61 Diseases Researched 106 Projects Funded 67 Institutions Funded 18 Success Stories $76 million Follow-On Raised by Researchers
January 2022

To Our Stakeholders:

On behalf of our Board of Directors, staff and many volunteers, it is my pleasure to share this summary of 2021. Even during the pandemic, we successfully expanded our mission’s reach and our scope. COVID19 continued to provide public examples of what we’ve known for over a decade: the fastest way to therapeutic impact is using approved therapies in randomized controlled trials.

2021 highlights:

- Nearly doubled our new clinical trial grant commitments over last fiscal year to $800,000.
- Launched our Pediatrics Initiative and our Diversity Equity & Inclusion (DEI) Initiative.
- Funded our first project in Vietnam / Asia.
- Held 3 virtual patient education and CureAccelerator Live! pitch events.
- Engaged more than 85 volunteer Grant Review Committee members, representing research, clinicians, industry and the patient / community voice.

We are grateful to all of our community members, both new and renewing, across all our disease areas, geographies and population groups – and look forward to an exciting 2022!

Barbara Goodman
President & CEO
Cures Within Reach improves patient quality and length of life by leveraging the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly. By supporting the unrealized clinical potential and missed therapeutic opportunities in existing medicine and science, we fund the clinical testing of already approved drugs, devices and nutraceuticals for unsolved diseases to serve both philanthropic and commercial needs.

Creating Patient Impact; Staying Focused on “Why”
Cures Within Reach and our partners are passionate about creating positive patient impact by developing “new” treatments through repurposing for patients with unsolved diseases, whether there is philanthropic opportunity or commercial value. Our current repurposing research portfolio covers a range of disease areas, from oncology and mental health to infectious diseases, rare diseases and inner ear disorders.

53% rare diseases
29% oncology
21% inner ear diseases
15% neurology (mental health and neurological)
12% infectious diseases
9% ophthalmic

68% adult; 32% pediatric
79% drug; 21% device/other
82% US-based; 18% outside US
91% clinical; 9% pre-clinical

as of 12.31.21

We are grateful for the support of our donors, sponsors and funding partners in making these exciting research studies a possibility.
2021 RESULTS

7 RFPs Lead to 16 New Trials Selected for Funding

During 2021, we had seven open funding opportunity Request for Proposals (RFPs): to impact veterans’ issues, pediatric rare diseases and health disparities; led by US-based underrepresented minority researchers and LMIC-based underserved researchers; and two for Meniere’s disease. These RFPs resulted in:

- 106 proposal submissions and more than 24 invitations for full grant applications
- Selection of 16 trials for funding – a 15% funding rate
- Engagement of more than 85 volunteer Grant Review Committee members, representing research, clinicians, industry and the patient / community voice

In addition to our robust RFP process in 2021, while the COVID19 pandemic certainly slowed our ongoing projects, our funded researchers were still able to publish, present and raise follow-on funding. We track our funded trials during the project timeline, and we follow them for a few years to measure success over time.

Research Aims:
Symptoms improved in depression and PTSD patients during clinical trial; publication in preparation

Patient Benefit:
Several early studies led by global partners show that fluvoxamine is effective at preventing hospitalization in COVID19-infected patients

Publications and Presentations:
Publications included our research(ers) in COVID19, Huntington’s disease, pancreatic cancer, brain cancer and several pediatric rare diseases

Follow-On Funding:
Nearly $9 million in new funding was reported during 2021 for ongoing trials, next phase or related projects

Follow-On Trials:
Active planning for follow-on trials in long COVID19 and lung cancer, among others

Impacting Patients More Broadly:
Market authorization in the US and other countries for a device treating multiple sclerosis
## NEW PROJECTS IN 2021

### 8 projects at 8 institutions in 7 diseases in 3 countries

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Institution</th>
<th>Title</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious Disease / Inner Ear / Rare</td>
<td>University of Utah</td>
<td>Repurposing the antiviral drug valganciclovir to treat Cytomegalovirus-Induced Hearing Loss</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Inner Ear</td>
<td>Stanford Medicine</td>
<td>Modulating inner ear fluid regulation to treat Meniere’s Disease</td>
<td>Drug / Pre-clinical</td>
</tr>
<tr>
<td>Neuro</td>
<td>Rush University Medical Center</td>
<td>Enhancing PTSD treatment for veterans via prebiotic supplementation</td>
<td>Nutraceutical / Adult</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>University of Cambridge, UK</td>
<td>Testing two generic drugs to improve outcomes in Osteosarcoma, a rare bone cancer</td>
<td>Drug / Pre-clinical</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>Loyola University of Chicago</td>
<td>Repurposing the blood pressure drug minoxidil for the treatment of recurrent chemo-resistant Ovarian Cancer</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>The University of Texas MD Anderson Cancer Center</td>
<td>Enhancing treatment response in recurrent / metastatic Osteosarcoma with hydroxychloroquine *</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Rare</td>
<td>Stanford University</td>
<td>Treating Vascular Malformations using the cancer drug trametinib *</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Rare</td>
<td>Vietnam National Children’s Hospital and Big Leap Research, Vietnam</td>
<td>Improving outcomes for the rare liver disease Biliary Atresia with a cancer drug</td>
<td>Drug / Pediatric</td>
</tr>
</tbody>
</table>

plus 11 more trials selected for funding in 2021, not yet started

These include traumatic brain injury, oncology, immune disease, chronic pain, Meniere’s disease and more, across 4 US states and 4 other countries

## PROJECTS COMPLETED IN 2021

### 4 projects at 4 institutions in 4 diseases in 2 countries

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Institution</th>
<th>Name</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI</td>
<td>Boston Children’s Hospital</td>
<td>Fecal microbiota transplantation patient registry for Pediatric C-diff</td>
<td>Other / Pediatric</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>Northwestern University</td>
<td>Testing an antidepressant (fluvoxamine) to slow progression of COVID-19</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Inner Ear</td>
<td>Curtin University, Australia</td>
<td>Testing a generic diuretic to improve drug delivery to the inner ear in Meniere’s Disease</td>
<td>Drug / Pre-clinical</td>
</tr>
<tr>
<td>Neuro</td>
<td>University of Pennsylvania Medicine</td>
<td>Using imaging techniques to guide targeted brain stimulation in the treatment of Depression and PTSD</td>
<td>Device / Adult</td>
</tr>
</tbody>
</table>

* winner of CureAccelerator Live!
## ONGOING PROJECTS IN 2021

**26 projects at 22 institutions in 21 Diseases in 5 countries**

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Institution</th>
<th>Title</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune</td>
<td>Massachusetts General Hospital</td>
<td>Repurposing a vaccine for Type I Diabetes</td>
<td>Vaccine / Adult</td>
</tr>
<tr>
<td>Autoimmune / Ophthalmology</td>
<td>Northwestern University</td>
<td>Treating Cataracts in Diabetic Patients using a surgical device</td>
<td>Device / Adult</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>Obafemi Awolowo University, Nigeria</td>
<td>Treating Tuberculosis with the lipid lowering drug atorvastatin in Nigeria</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>George Washington University, Universidad El Bosque</td>
<td>Repurposing a flu treatment for Severe Dengue patients in Colombia</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>University of Chicago</td>
<td>Can Vitamin D reduce the burden of COVID-19 in Chicago?</td>
<td>Nutraceutical / Adult</td>
</tr>
<tr>
<td>Inner Ear</td>
<td>Dent Neurologic Institute</td>
<td>Combining an anti-epileptic drug with an anti-anxiety drug to treat the inner ear disorder Meniere's Disease</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Inner Ear</td>
<td>Hospital of the Ludwig-Maximilians University, Germany</td>
<td>Combining a vertigo drug with a Parkinson's disease drug to treat the inner ear disorder, Meniere's Disease</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Inner Ear</td>
<td>House Ear Institute</td>
<td>Reducing vertigo and hearing loss in Meniere's Disease by repurposing a common allergy drug</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Inner Ear</td>
<td>Feinstein Institutes for Medical Research</td>
<td>Investigating the effects of repurposed diuretic, steroid and immunosuppressive drugs in Meniere's Disease</td>
<td>Drug / Pre-clinical</td>
</tr>
<tr>
<td>Inner Ear</td>
<td>Medical University of South Carolina</td>
<td>Assessing the efficacy of an antidepressant for improving vertigo attacks in Meniere's Disease</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Neuro</td>
<td>Pennsylvania State University, Milton S. Hershey Medical Center</td>
<td>Repurposing a Multiple Sclerosis drug in Severe Limb Trauma *</td>
<td>Drug Into Diagnostic / Adult</td>
</tr>
<tr>
<td>Neuro</td>
<td>Shirley Ryan AbilityLab</td>
<td>Repurposing a blood cancer treatment to treat muscle contractures in Cerebral Palsy patients *</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Neuro / Rare</td>
<td>Georgetown University</td>
<td>Using a cancer drug in Huntington's Disease</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Neuro / Rare</td>
<td>University of Texas Health Science Center at Houston</td>
<td>Treating irritability in Huntington's Disease with a repurposed neurological drug</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Oncology</td>
<td>The Hospital for Sick Children, Canada</td>
<td>Low-level laser therapy to address treatment side effects in Pediatric Cancer patients</td>
<td>Device / Pediatric</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>Children's Hospital of Philadelphia</td>
<td>Preventing relapse after bone marrow transplant in Pediatric Acute Lymphoblastic Leukemia with a personalized treatment</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>University of California, Irvine</td>
<td>Treating a group of rare blood cancers, Myeloproliferative Neoplasms, with N-acetylcysteine *</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>Massachusetts General Hospital / Harvard, VUmc Cancer Center Amsterdam</td>
<td>A novel combination of generic chemotherapy drugs to treat Brain Cancer</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>University of Michigan</td>
<td>Repurposing old drugs as new therapies for Metastatic Thyroid Cancer*</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>University of Michigan</td>
<td>Improving patient response in Mantle Cell Lymphoma with venetoclax</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Oncology / Rare</td>
<td>University of Michigan</td>
<td>Using a skin cancer drug to improve current treatment in a Rare Blood Cancer</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Ophthalmology / Rare</td>
<td>University of California, Davis</td>
<td>Repurposing bone marrow stem cell therapy for vision loss caused by Retinitis Pigmentosa</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Ophthalmology / Rare</td>
<td>University of Michigan</td>
<td>Testing a generic malaria drug in a Rare Ophthalmic Condition</td>
<td>Drug / Adult</td>
</tr>
<tr>
<td>Rare</td>
<td>Hospital for Sick Children, National Institutes of Health</td>
<td>TAM4MTM: Tamoxifen therapy for Myotubular Myopathy</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Rare</td>
<td>St. Jude Children's Research Hospital</td>
<td>Repurposing a blood cancer drug to treat an immune disorder (HLH) in children *</td>
<td>Drug / Pediatric</td>
</tr>
<tr>
<td>Other</td>
<td>KEMRI-Wellcome Trust Research Programme, Kenya</td>
<td>Testing the safety of a metal poisoning drug to treat Snakebite</td>
<td>Drug / Adult</td>
</tr>
</tbody>
</table>

* winner of CureAccelerator Live!
Our Focus: patient access to viable treatments while building a pipeline of opportunities. We aren’t funding therapeutic development to the finish line, but providing seed funds to achieve catalytic effect.

Additive to Pharma Industry’s Life Cycle Management:
Mid-stage: on-patent, but small indication or off-strategy
Later stage: generic or new delivery method
In 2021, we continued building our nine repurposing communities to align with our stakeholders’ strategic interests:

- **Disease-specific:** Oncology; Neurology; and Rare Diseases
- **Geographic:** Chicago; Mid-Atlantic; and the Developing World
- **Populations:** Pediatrics; Veterans / Military; and Minorities / Underserved: Diversity, Equity & Inclusion

Most of our trials overlap communities. For example, our newest clinical trial in pediatric osteosarcoma impacts our Pediatrics, Oncology and DEI communities.

Our virtual communities engage key stakeholders:

- Patient groups and disease associations
- Universities and research institutions
- Healthcare industry
- Philanthropy, government and others
Clinical Repurposing to Impact Pediatrics: 2021 Results

In early 2021, we launched this new Pediatric Community with a call for proposals in Pediatric Rare Diseases.

- 21 proposals received from 7 countries
- 12 Grant Review Committee members recruited, representing research, clinicians, industry, philanthropy and the patient voice
- 4 finalists invited to pitch at our June event
- 3 new clinical trials now underway

**Of our 34 ongoing trials at year-end, 10 are in Pediatrics**

Pediatric Finalists

- Ignacia Fuentes, PhD of DEBRA Chile: Repurposing a Common Antioxidant Nutraceutical, N-Acetylcysteine, for Wound Treatment in Butterfly Skin
- Nancy Gordon, MD of the University of Texas MD Anderson Cancer Center: Enhancing Treatment Response in Recurrent / Metastatic Osteosarcoma with Hydroxychloroquine
- Joseph Rower, PhD of University of Utah: Repurposing Valganciclovir to Treat Cytomegalovirus-Induced Hearing Loss
- Joyce Teng, MD, PhD of Stanford University: Treating Vascular Malformations in the Face, Head and Neck using Trametinib

"CUREACCELERATOR® Live!" for Pediatric Rare Diseases on June 10

During 2021, we held our CureAccelerator Live! philanthropic pitch event virtually. This event:

- Brings clinical research to a public setting
- Showcases 3 to 5 projects selected from an RFP via an external review committee
- Selects a winning clinical repurposing project after Q&A from an expert panel
Clinical Repurposing for Veterans: 2021 Results

Our Veterans Initiative launched on Veterans Day, Nov 2020 with a call for proposals to impact veterans’ issues

- 32 proposals received from 18 states and Washington, DC, and more than 55% are from or collaborating with a VA institution; 6 proposals invited to submit full grant application
- 22 Grant Review Committee members recruited (representing research, clinicians, industry, and the patient / veterans voice)
- 2 clinical trials selected: in traumatic brain injury at the University of New Mexico and in PTSD at Rush University Medical Center

Of our 34 ongoing trials at year-end, 3 are in Veterans/Military

Proposals by Disease Area
31% mental health (PTSD, depression)
38% other neuro (pain, substance abuse, TBI)
6% stroke
6% oncology
6% cardiovascular
13% other areas

Proposals by Location

Lead Philanthropic Partner:
THE KAHLERT FOUNDATION
Clinical Repurposing for Underrepresented Researchers and Patients: 2021 Results

Our new **Diversity Equity & Inclusion Community** launched in 2021

- 2 Funding Opportunity RFPs
  - Clinical trials led by US-Based **Racial / Ethnic Minority Scientists** in any disease
  - Clinical trials to address **Racial / Ethnic Health Disparities in Chicagoland**
- 22 proposals received from 12 states
- 25 Grant Review Committee members recruited, including more than 60% Black/Hispanic members (**representing research, clinicians, industry and the patient / community voice**)
- 13 invited to submit full grant applications
- 5 new trials selected for funding, including several with community-based organization engagement

*Of our 34 ongoing trials at year-end, 3 are in US-based DEI*

---

**Proposals by Disease Area**
- 32% genetic / other
- 27% rare
- 23% oncology
- 23% neuro
- 18% infectious diseases
- 5% cardiovascular

**Proposals by Researcher**
- 41% Black/African
- 18% Hispanic/Latinx
- 18% Mixed Race/Other
- 18% Caucasian (**health disparities projects**)
- 5% Native Hawaiian/Pacific Islander

---

**Lead Philanthropic Partners:**

The Searle Funds at The Chicago Community Trust

Takeda

**Additional Philanthropic Partners:**

Adtalem Global Education Foundation
Burroughs Wellcome Fund
bcu
Horizon

Susie and David Sherman

Walder Foundation
Clinical Repurposing to Build Clinical Trial Capacity in Low/Lower-Middle Income Countries (LMICs): 2021 Results

In 2021, we opened our 2nd RFP for clinical trials led by LMIC-based underserved scientists in any disease

- 24 proposals received from 10 countries on 3 continents
- 21 Grant Review Committee members recruited (representing research, clinicians, industry, philanthropy, the patient voice and the global health community)
- 7 invited to submit full grant applications
- 3 new trials selected for funding

Of our 34 ongoing trials at year-end, 3 are in LMIC-based DEI

MINORITY / UNDERSERVED COMMUNITY: RESEARCHERS BASED IN LOW AND LOWER-MIDDLE INCOME COUNTRIES

2021 Proposals by Disease Area
- 33% oncology
- 22% infectious diseases
- 11% inflammation/ear
- 11% neurology
- 7% rare
- 22% other

2020 and 2021 Submissions by Country

Lead Philanthropic Partner:

Takeda
DONOR ADVISED IMPACT PHILANTHROPY

**CWR’s Value Proposition:**
- Access to our 50+ research partner network
- A two-stage due diligence process using external grant reviewers, representing research, industry, clinicians and the patient voice, to support project selection
- Expertise in finding, selecting, de-risking and managing our funded clinical trials
- Both project and financial progress reports during and after the project

CWR funding often catalyzes follow-on funding from the NIH, foundations, industry and investors.

**Philanthropy with faster patient impact**
- Funding partners and donors have flexibility and control over involvement during the search, selection and approval processes
- Research grants starting at $50,000 can support a small, proof-of-concept human clinical trial

**Donor-advised funding can support a specific disease, geography, patient population or other theme**
- Impacting Veterans’ Issues
- In Pediatrics
- Impacting Health Disparities
- Led by Minority or Underserved Researchers
- In a specific disease area or geography

“Repurposing research seems to be an area tailor-made for wider philanthropic support. Philanthropy can be less concerned with the financial returns on its investments... In the process, they might make a huge difference in the lives of people who have few other avenues for hope.”

*Paul Karon, Inside Philanthropy*
to honor the impact that its screening database is having on patients with neglected diseases as well as finding potential COVID-19 treatments. We celebrate Calibr’s commitment to the database’s ease of accessibility and the collaboration made possible through this technology, especially during the COVID-19 pandemic. Since ReFRAME’s launch, repurposed drugs such as clofazimine in cryptosporidiosis and auranofin in TB are impacting patients in clinical trials.

Accepting on behalf of ReFRAME: Arnab Chatterjee, PhD, Vice President

2021 Janet Davison Rowley Patient Impact Research Award

2021 Golan Christie Taglia Patient Impact Philanthropy Award

Accepting on behalf of CURE ID: Heather Stone, MPH, Health Science Policy Analyst

Accepting on behalf of ReFRAME: Arnab Chatterjee, PhD, Vice President

2021 Patient Impact Industry Award

Accepting on behalf of Lilly: Robert Baker, MD, Deputy Chief Medical Officer

to honor its ongoing commitment to improving the lives of patients with unmet medical needs. During the COVID-19 pandemic, this has been through its support of baricitinib, an existing rheumatoid arthritis medication, to treat certain hospitalized COVID-19 patients, among other initiatives. Baricitinib has been authorized for emergency use by the FDA in combination with remdesivir. In addition, Lilly has continued to test already approved therapies for new indications, including duloxetine for fibromyalgia and ramucirumab for various cancers after it was first approved for stomach cancer.
As part of our Repurposing Communities programming, we represented the voice of repurposing when we organized, spoke at or participated in a variety of **patient education events** throughout 2021.

### Real World Data Through a Patient’s Lens
**October 12, 2021 from 1:00pm to 2:30pm ET**

A conversation on **Real World Data (RWD) and case reports from clinicians and researchers**. This patient education event will focus on what RWD means, the importance of RWD in clinical decision making, RWD and off-label usage by doctors and patients, the role patients and caregivers can play in collecting RWD, and how patients and caregivers can utilize RWD to impact their own healthcare. Speakers will provide the perspectives of industry, payers, clinicians, nonprofits and the patient voice.

### Diversity of Clinical Trial Researchers and Patients: A Repurposing Opportunity?
**November 9, 2021 from 1:00pm to 2:45pm ET**

A dialogue on **the dual opportunities of clinical trial diversity to impact health disparities and/or improve minority leadership in scientific research**. Topics include the importance of diversity in finding treatments for unsolved diseases, health disparities and the role of repurposed therapies in addressing them; community organizations’ role in clinical research diversity; and the need to reduce the NIH funding gap for underrepresented racial/ethnic minority researchers. Speakers will provide the perspectives of industry, research, clinicians, community organizations and the patient voice.

During the event, there will be a showcase of our ongoing clinical trials within our Diversity, Equity & Inclusion Community, including projects impacting health disparities and led by racial/ethnic minority and underserved scientists.
This annual golf fundraiser, held again at Rich Harvest Farms, raised nearly $70,000 towards our mission. A portion of the proceeds in 2021 helped fund our pediatric rare diseases trials. Thanks to Co-Chairs Steve Goodfriend and Bobby Miller!
BY THE NUMBERS

FY2021 Income
By Source

- Private Foundations, 50%
- Individuals, 25%
- Healthcare Industry, 24%
- Other, 2%

BY GEOGRAPHY

In addition to the 28 ongoing trials across the US, our ongoing projects are also in:
- Canada
- Germany
- Kenya
- Nigeria
- United Kingdom
- Vietnam

Revenue

<table>
<thead>
<tr>
<th></th>
<th>FY2018</th>
<th>FY2019</th>
<th>FY2020</th>
<th>FY2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$0</td>
<td>$500,000</td>
<td>$1,000,000</td>
<td>$1,500,000</td>
</tr>
</tbody>
</table>

As of 1.15.2022
Board of Directors
Margaret Christie, JD, Chair, Golan Christie Taglia LLP
Lucy Mancini-Newell, Secretary, Consultant
Matthew Rich, Treasurer, PwC
Kristina Allikmets, MD, PhD, Takeda Pharmaceuticals
Steve Braun, Northwestern Mutual
Nick Manusos, MagSeven LLC
Robert Metz, Armour Life Sciences
David Styler, Horizon Therapeutics
Nancy Sullivan, IllinoisVENTURES llc

Science Advisory Board
Jeff Sherman, MD, Chair, Horizon Therapeutics
Andrés Klein, PhD, Vice-Chair, Universidad del Desarrollo
Kevin B. Clark, PhD, Past Chair, Consultant to NASA/IEEE/others
Luis Caveda, PhD, Axogen
Tim Cunniff, PharmD, Paragon Pharmaceuticals
Douglas Feinstein, PhD, University of Illinois at Chicago
Shuli Kulak, MD, AavantiBio
Murray Lumpkin, MD, MSc, Bill and Melinda Gates Foundation
Wilfred Ngwa, PhD, MSc, Johns Hopkins University
Larry Sklar, PhD, University of New Mexico
Vidula Sukhatme, MS, GlobalCures and Emory University

Business Development / Commercialization Committee
Adam Elhofy, PhD, Cour Pharmaceutical
Ed Kahn, Rediscovery Life Sciences
Robert Metz, Armour Life Sciences
Norbert Riedel, PhD, Aptinyx
Michael S. Rosen, Rosen BioScience Strategies, Rosalind Franklin University
Adriann Sax, VetiGenics
Eric Waehner, Recordati Rare Diseases

Cures Within Reach
Barbara Goodman, President & CEO
Clare Thibodeaux, PhD, Vice President, Scientific Affairs
with support from additional staff, interns and consultants

Cures Within Reach is also grateful for the support in 2021 from over 85 volunteer Grant Review Committee Members who reviewed, ranked and scored over 100 proposals and over 20 full grant applications.
2021 COMMUNITY MEMBERS AND PARTNERS

Anonymous  Arlene and Tom Alm  Margie Christie  Joe and Mari Dysart  Lori and Bobby Miller  Susie and David Sherman

Cures Within Reach
134 North LaSalle Street, Suite 1130
Chicago, Illinois 60602
(847) 745-1252
info@cureswithinreach.org